ASCLETIS-B (01672) climbed more than 6% in Hong Kong trading, extending recent gains. At the time of writing, the stock was up 5.52% to HK$17.2, with a turnover of HK$69.458 million. The rally follows news that GIC secured a leading allocation in ASCLETIS-B's latest placement, which is expected to accelerate the global Phase III clinical development of ASC30. On February 6, Hong Kong Exchange disclosures revealed that Singapore's sovereign wealth fund GIC purchased approximately 64.128 million new shares of ASCLETIS-B at an average price of HK$12.18 per share, investing about HK$781 million. Following the transaction, GIC holds a 6.42% stake in the company. Oriental Securities noted that ASC30 demonstrates superior weight loss data and favorable safety profiles, with its molecular patent already granted in the United States, indicating significant business development potential. Additionally, ASCLETIS-B has developed a subcutaneous formulation of ASC30 based on its ultra-long-acting platform (ULAP) for weight loss and maintenance therapy. The formulation exhibits apparent half-lives of 46 days and 75 days, respectively, far exceeding those of other ultra-long-acting GLP-1 drugs, while maintaining a strong safety advantage.